SEC Form 4
Aquestive Therapeutics, Inc. (AQST) insider trading
In the 12 months to Oct 26, 2026, 3 AQST insiders reported open-market sales of $743.9K across 8 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $743.9K
- 8 filings · 3 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 8 of 8
- All $743.9K sold was pre-arranged
Who traded AQST, and when
- Sale
- Sale, pre-arranged (10b5-1)
AQST daily close from Oct 27, 2025 to Oct 26, 2026, between $2.95 and $7.00, last $3.99. 8 sale and 0 purchase filings by 3 insiders, marked at their filing dates. Daniel Barber, President and CEO: sold $572.9K across 6 filings, first filed May 18, 2026, last Oct 16, 2026. Julie Krop, Director: sold $125.4K across 1 filing, first filed Jun 24, 2026, last Jun 24, 2026. Sherry Korczynski, Chief Commercial Officer: sold $45.7K across 1 filing, first filed Sep 11, 2026, last Sep 11, 2026.
Largest mark · tap a row for others
Julie Krop · Director
Sale $125,393
25,000 shares at $5.02 avg
Filed Jun 24, 2026 · traded Jun 23
Pre-arranged (10b5-1) · close on filing date $4.99
Daniel Barber · President and CEO
President and CEO
$572.9K soldJulie Krop · Director
Director
$125.4K soldSherry Korczynski · Chief Commercial Officer
Chief Commercial Officer
$45.7K soldOpen-market trades
8 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Daniel Barber | President and CEO | $572.9K | — | 6 | 100% of sales | |
| Julie Krop | Director | $125.4K | — | 1 | 100% of sales | |
| Sherry Korczynski | Chief Commercial Officer | $45.7K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Daniel Barber President and CEO | SalePre-arranged (10b5-1) | 25,000 | $4.22 | $105.6K | 627,317 | |
traded | Daniel Barber President and CEO | SalePre-arranged (10b5-1) | 25,000 | $4.82 | $120.5K | 652,317 | |
traded | Sherry Korczynski Chief Commercial Officer | SalePre-arranged (10b5-1) | 8,750 | $5.22 | $45.7K | 235,689 | |
traded | Daniel Barber President and CEO | SalePre-arranged (10b5-1) | 25,000 | $4.29 | $107.2K | 585,574 | |
traded | Daniel Barber President and CEO | SalePre-arranged (10b5-1) | 25,000 | $4.01 | $100.2K | 610,574 | |
traded | Julie Krop Director | SalePre-arranged (10b5-1) | 25,000 | $5.02 | $125.4K | 0 | |
traded | Daniel Barber President and CEO | SalePre-arranged (10b5-1) | 25,000 | $4.16 | $104.0K | 635,574 | |
traded | Daniel Barber President and CEO | SalePre-arranged (10b5-1) | 8,257 | $4.29 | $35.4K | 660,574 |
GET /stocks/filings/vX/form-4?tickers=AQST&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"AQST"
],
"issuer_cik": "0001398733",
"owner_cik": "0001742266",
"accession_number": "0001214659-26-012986",
"form_type": "4",
"filing_date": "2026-10-16",
"period_of_report": "2026-10-15",
"issuer_name": "Aquestive Therapeutics, Inc.",
"issuer_trading_symbol": "AQST",
"owner_name": "Barber Daniel",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President and CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-15",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 25000,
"transaction_price_per_share": 4.224,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 627317,
"transaction_value": 105600,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The reported transaction involves sale transactions from $4.03 to $4.68 per share. The weighted average price per share was $4.2240. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price."
}
]
},
{
"tickers": [
"AQST"
],
"issuer_cik": "0001398733",
"owner_cik": "0001742266",
"accession_number": "0001214659-26-011731",
"form_type": "4",
"filing_date": "2026-09-16",
"period_of_report": "2026-09-15",
"issuer_name": "Aquestive Therapeutics, Inc.",
"issuer_trading_symbol": "AQST",
"owner_name": "Barber Daniel",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President and CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-15",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 25000,
"transaction_price_per_share": 4.8195,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 652317,
"transaction_value": 120487.49999999999,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The reported transaction involves sale transactions from $4.78 to $4.90 per share. The weighted average price per share was $4.8195. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 35 records
- Option exercises2 records
- Tax withholding10 records
- Tax withholding (sold to cover)7 records
- Grants and awards12 records
- Other4 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Aquestive Therapeutics, Inc.'s CEO sold stock?
Yes. Daniel Barber (CEO) sold 133,257 shares ($572.9K) between May 2026 and Oct 2026, all under a pre-arranged 10b5-1 plan.
How current is AQST’s insider data?
These are AQST Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track AQST insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for AQST every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.